Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
Ziccheddu, B.; Giannotta, C.; D'Agostino, M.; Bertuglia, G.; Saraci, E.; Oliva, S.; Genuardi, E.; Papadimitriou, M.; Diamond, B.; Corradini, P.; Coffey, D.; Landgren, O.; Bolli, N.; Bruno, B.; Boccadoro, M.; Massaia, M.; Maura, F.; Larocca, A.
Show abstract
Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). Whole genome sequencing (WGS) before and after treatment pinpointed genomic drivers associated with early progression, including RPL5 loss and APOBEC mutagenesis. Flow cytometry on 202 blood samples, collected every three months until progression for 31 patients, revealed distinct immune changes significantly impacting clinical outcomes. Progressing patients exhibited significant depletion of CD38+ NK cells, persistence of T cell exhaustion, and reduced depletion of T-reg cells over time. These findings underscore the influence of immune composition and daratumumab-induced immune changes in promoting MM resistance. Integrating genomics and flow cytometry unveiled associations between adverse genomic features and immune patterns. Overall, this study sheds light on the intricate interplay between genomic complexity and the immune microenvironment driving resistance to Dara-Rd.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes 96%
- Accelerated single cell seeding in relapsed multiple myeloma 95%
- Copy number signatures predict chromothripsis and associate with poor clinical outcomes in patients with newly diagnosed multiple myeloma 95%
Similar papers in this journal
- First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer 93%
- CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia 92%
- Treatment with Soluble CD24 Attenuates COVID-19-Associated Systemic Immunopathology 92%
Similar papers in this journal
- An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia 94%
- Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer. 93%
- Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial 93%
Similar papers in this journal
- Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia 95%
- CXCL8 secreted by immature granulocytes inhibits wildtype hematopoiesis in chronic myelomonocytic leukemia 93%
- Expansion, persistence and efficacy of donor memory-like NK cells for the treatment of post-transplant relapse 93%
Similar papers in this journal
- Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases 93%
- Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers 93%
- DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.